Aug, 2018
Rutaecarpine attenuates osteoclastogenesis by impairing macrophage colony stimulating factor and receptor activator of nuclear factor κ-B ligand-stimulated signalling pathways.
Clinical and experimental pharmacology & physiology
- ,
- ,
- ,
- ,
- ,
- Volume
- 45
- Number
- 8
- First page
- 863
- Last page
- 865
- Language
- English
- Publishing type
- DOI
- 10.1111/1440-1681.12941
Rutaecarpine is a major alkaloid isolated from Evodia rutaecarpa. Here, we investigated the effects of rutaecarpine on osteoclast differentiation induced by macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor κ-B ligand (RANKL) in bone marrow-derived macrophages (BMMs). Treatment with rutaecarpine significantly inhibited osteoclastogenesis and prevented bone resorption of BMM-derived osteoclasts. Mechanistically, rutaecarpine decreased the protein level of nuclear factor of activated T cells cytoplasmic-1 (NFATc1) and the phosphorylation of other signalling pathways during the osteoclast differentiation. Thus, rutaecarpine may be useful as a therapeutic agent for the treatment of bone diseases.
- Link information
- ID information
-
- DOI : 10.1111/1440-1681.12941
- Pubmed ID : 29582460